CHARLOTTESVILLE, Va., April 22, 2020 /PRNewswire/ — Biovista, a privately-held AI / bioscience firm best known for drug repositioning, has identified four treatments – two prescription drugs and two over-the-counter compounds — to counter key symptoms of COVID-19. “Drug AI helps find that needle in the haystack, and we are optimistic that we have found four … Read More
The latest version of Biovista Vizit introduces two much requested features: A new High Throughput Layout, and A new Copy/Paste mechanism to transfer named Entities in and out of Vizit. Here’s a quick rundown of the new features: High Throughput Layout Biovista Vizit is frequently used for systematic exploration of a biomedical domain. For example, … Read More
Biovista is pleased to announce the signature of a grant agreement within the remit of the EU’s Innovative Medicines Initiative (IMI). Starting in March 2019, the 3.5 year “NeuroDeRisk” project aims to advance the industry’s ability to tackle three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Together with EFPIA members … Read More
Article by Merle Giles, September 19, 2017 A breath of fresh air came from Graham Anthony who spoke about the pursuit of sustainable healthcare through personalized medicine. The Biovista website calls it ‘drug repositioning’ when HPC drives the ability to more effectively and quickly combine patient and general biomedical data to transform medicine. The key … Read More
Presentation- Pursuit of Sustainable Healthcare through Personalized Medicine with HPC View the presentation by Biovista’s Graham Anthony at the HPC User Forum, Milwaukee 2017.